A novel drug administration Schedule of amphotericin B for childhood acute leukemia with Invasive Fungal Disease.

A randomized comparative trial evaluating the different drug administration Schedule of conventional amphotericin B for empirical treatment in childhood acute leukemia with Invasive Fungal Disease.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011449

Enrollment

Unknown

Registered

2017-05-20

Start date

2006-01-02

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric leukaemia

Interventions

Group A:6 day slow dose escalation strategy (0.1-0.2-0.3-0.4-0.5-0.7mg/kg) of amphotericin B

Group B:3 day slow dose escalation strategy (0.2-0.4-0.7mg/kg) of amphotericin B

Eligibility

Sex/Gender

All

Age

1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Had received chemotherapy for leukemia who have a need to treated with empirical antifungal therapy; 2. The typical radiological appearance of nodules,cavities orhalo signlesion; 3. Meet the msycological criteria.

Exclusion criteria

Exclusion criteria: 1. Combined with other antifungal; 2. Medicinesserum levels of aspartate aminotransferase,alanine aminotransferase,or bilirubin that were more than five times the upper limit of normal; 3. Had renal dyfunction.

Design outcomes

Primary

Measure	Time frame
efficacy;Adverse events;lymphocyte subsets ratio;	—

Countries

China

Contacts

Public ContactMinghua Yang

Xiangya Hospital, Central South University

yamahua123@163.com+86 13973135843

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026